PMA device
Signatera CDx
Natera, Inc. · Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP, Class III) · First FDA decision May 15, 2026, newest May 15, 2026Cancer detection and genomic testing
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
0
Naming "Signatera CDx"
MAUDE reports
0
Brand "Signatera CDx", since 2015
PubMed studies
0
Mentioning "Signatera CDx"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Signatera CDxBreakthroughPMA
P260004 · Decided May 15, 2026 · 106 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40210Palmetto GBAUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40278WPS Insurance CorporationUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40226CGS Administrators, LLCUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40222Noridian Healthcare Solutions, LLCUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40278WPS Insurance CorporationUpdated Sep 15, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40222Noridian Healthcare Solutions, LLCUpdated Aug 22, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40226CGS Administrators, LLCUpdated Aug 21, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40210Palmetto GBAUpdated Aug 18, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "Signatera CDx", any status and sponsor, newest update first.
No registered device study names "Signatera CDx".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Signatera CDx", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PQP
14 reports: 11 malfunction, 2 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Signatera CDx"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code PQP.
- FoundationOne CDxFoundation Medicine, Inc. · PMA 2026
- FoundationOne Liquid CDxFoundation Medicine, Inc. · PMA 2026
- Oncomine Dx Target TestLife Technologies Corporation · PMA 2025
- Guardant360 CDxGuardant Health, Inc. · PMA 2026
- Oncomine Dx Express TestLife Technologies Corporation · PMA 2026
- xT CDxTempus AI, Inc. · PMA 2026
- TruSight Oncology ComprehensiveIllumina, Inc. · PMA 2026
- FoundationOne®Liquid CDxFoundation Medicine, Inc. · PMA 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.